Thymic carcinoma medical therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Marjan Khan M.B.B.S.[2]
Overview
The predominant therapy for thymic carcinoma is surgical resection. Adjunctive cisplatin-based chemotherapy may be required.[1]
Medical Therapy
Medical treatment options for thymic carcinoma include the following:[1]
- CAP regimen (cyclophosphamide, doxorubicin, cisplatin): this is the first-line regimen
- Sunitinib[2]
- Gemcitabine
- Docetaxel
- Checkpoint inhibitors
- Radiation
Multimodality approach, such as:
- Surgical resection
- Radiation therapy
- Cisplatin-based chemotherapy
References
- ↑ 1.0 1.1 National Cancer Institute. General Information About Thymoma and Thymic Carcinoma Treatment. http://www.cancer.gov/types/thymoma/hp/thymoma-treatment-pdq. Accessed on 22nd December, 2015.
- ↑ Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ; et al. (2015). “Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial”. Lancet Oncol. 16 (2): 177–86. doi:10.1016/S1470-2045(14)71181-7. PMC 4401497. PMID 25592632.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH